

## **Paloma Pharmaceuticals Presents Activity of P529 in an Infantile Spasm Animal Model**

**-- Data presented at the American Neurological Association Annual Meeting --**

Jamaica Plain, MA, 14 September 2010 -- Paloma Pharmaceuticals, Inc. announced today new data showing positive activity of Palomid 529 (P529), Paloma Pharmaceuticals first-in-class allosteric dual TORC1/TORC2 dissociative inhibitor targeting the PI3K/Akt/mTOR pathway, in a rat infantile spasm model carried out by Dr. Aristeia S. Galanopoulou M.D., Ph.D., Albert Einstein College of Medicine, Bronx, NY at the 135<sup>th</sup> Annual Meeting of the American Neurological Association in San Francisco, CA, "Palomid 529, a Combined TORC1/TORC2 Inhibitor, Suppresses Spasms in a Rat Model of Infantile Spasms".

Infantile spasm is an epileptic syndrome manifesting with clusters of flexion or extension spasms in infants and is associated with severe epileptic encephalopathy, intractable epilepsies and cognitive deficits. Currently, first line medication for infantile spasm is adrenocorticotropin hormone or vigabatrin, which need to be given for long periods of time, are often associated with significant adverse effects and are not always effective. Hence, there is a clear urgency to identify novel therapies for catastrophic epileptic encephalopathies.

P529 was evaluated in a rat model of infantile spasm. P529 effectively suppressed spasms acutely, within 2 hours of administration; its therapeutic effect was sustained throughout the period of administration and was not associated with rebound seizure exacerbation following discontinuation of drug. Repetitive P529 administration did not cause weight loss or decreased growth and did not show any significant drug-associated mortality. Pups which experienced spasms and were treated with P529 also showed improved motility and exploratory behavior following resolution of spasms compared to vehicle-treated pups.

"We were pleased to find P529 able to suppress spasms in the infantile spasm model. As there are no effective treatments for this devastating disease, our hope is that P529 will show activity in the clinic in the not too distant future," said Dr. David Sherris, President and CEO of Paloma Pharmaceuticals.

### **About Paloma Pharmaceuticals**

Paloma Pharmaceuticals, Inc. is a drug development company using PI3K/Akt/mTOR inhibitors for cancer, ocular, CNS, fibrotic, antiviral, biodefense and skin diseases. Paloma owns intellectual property relating to a library of novel, proprietary, small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard computational tools.

SOURCE Paloma Pharmaceuticals, Inc.

<http://www.palomapharma.com>.